{"id":"phenmetrazine","rwe":[{"pmid":"39903277","year":"2025","title":"Toxicokinetics and analytical toxicology of the phenmetrazine-derived new psychoactive substance 3,4-methylenedioxyphenmetrazine studied by means of in vitro systems.","finding":"","journal":"Archives of toxicology","studyType":"Clinical Study"},{"pmid":"38499566","year":"2024","title":"Co-targeting the kappa opioid receptor and dopamine transporter reduces motivation to self-administer cocaine and partially reverses dopamine system dysregulation.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"37968919","year":"2023","title":"Stimulant and hallucinogenic novel psychoactive substances; an update.","finding":"","journal":"Expert review of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"36871726","year":"2023","title":"Target and suspect screening of (new) psychoactive substances in South Korean wastewater by LC-HRMS.","finding":"","journal":"The Science of the total environment","studyType":"Clinical Study"},{"pmid":"36028947","year":"2022","title":"Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis.","finding":"","journal":"Basic & clinical pharmacology & toxicology","studyType":"Clinical Study"}],"tags":[{"label":"phenmetrazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent noradrenaline transporter","category":"target"},{"label":"SLC6A2","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"MAOA","category":"gene"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Obesity","category":"indication"},{"label":"Boehringer Ingelheim","category":"company"},{"label":"Anti-Obesity Agents","category":"pharmacology"},{"label":"Appetite Depressants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Stimulants","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Alcoholism","Arteriosclerotic vascular disease","Breastfeeding (mother)","Chronic heart failure","Conduction disorder of the heart","Diabetes mellitus type 1","Diabetes mellitus type 2","Disorder of coronary artery","Drug-induced psychosis","Epilepsy","Feeling agitated","Glaucoma","Heart valve disorder","Hypertensive disorder","Hypertensive urgency","Hyperthyroidism","Pulmonary hypertension","Substance abuse"]},"trials":[],"aliases":[],"company":"Boehringer Ingelheim","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PHENMETRAZINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:05:37.940434+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:05:44.097778+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENMETRAZINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:05:44.626534+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201208/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:05:45.342460+00:00"}},"allNames":"fenmetrazina","offLabel":[],"synonyms":["phenmetrazine teoclate","fenmetrazine","phenmetrazine hydrochloride","phenmetrazine","3-Methyl-2-phenylmorpholine","3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine","oxazimedrine","phenmetrazin","fenmetrazina","phenmetrazine HCl"],"timeline":[],"approvals":[{"date":"","orphan":false,"company":"BOEHRINGER INGELHEIM","regulator":"FDA"}],"brandName":"Fenmetrazina","ecosystem":[{"indication":"Obesity","otherDrugs":[{"name":"amfetamine","slug":"amfetamine","company":"Ucb Inc"},{"name":"benzphetamine","slug":"benzphetamine","company":"Pharmacia And Upjohn"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"chlorphentermine","slug":"chlorphentermine","company":"Parke Davis"}],"globalPrevalence":890000000}],"mechanism":{"target":"Sodium-dependent noradrenaline transporter","novelty":"First-in-class","targets":[{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"MAOA","source":"DrugCentral","target":"Amine oxidase [flavin-containing] A","protein":"Amine oxidase [flavin-containing] A"}],"modality":"Small Molecule","drugClass":"phenmetrazine","explanation":"","oneSentence":"","technicalDetail":"Fenmetrazine acts as a non-selective inhibitor of the sodium-dependent noradrenaline transporter (NET), leading to increased levels of noradrenaline in the synaptic cleft and enhanced neurotransmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2133","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENMETRAZINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:18:23.330317","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:05:47.374370+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"amfetamine","drugSlug":"amfetamine","fdaApproval":"1955-09-09","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atomoxetine","drugSlug":"atomoxetine","fdaApproval":"2002-11-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"benzatropine","drugSlug":"benzatropine","fdaApproval":"1954-03-05","relationship":"same-target"},{"drugName":"benzethonium","drugSlug":"benzethonium","fdaApproval":"","relationship":"same-target"},{"drugName":"benzphetamine","drugSlug":"benzphetamine","fdaApproval":"1960-10-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"phenmetrazine","indications":{"approved":[{"name":"Obesity","source":"DrugCentral","snomedId":414916001,"regulator":"FDA","usPrevalence":100000000,"globalPrevalence":890000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"amfetamine","brandName":"amfetamine","genericName":"amfetamine","approvalYear":"1955","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atomoxetine","brandName":"atomoxetine","genericName":"atomoxetine","approvalYear":"2002","relationship":"same-target"},{"drugId":"benzatropine","brandName":"benzatropine","genericName":"benzatropine","approvalYear":"1954","relationship":"same-target"},{"drugId":"benzethonium","brandName":"benzethonium","genericName":"benzethonium","approvalYear":"","relationship":"same-target"},{"drugId":"benzphetamine","brandName":"benzphetamine","genericName":"benzphetamine","approvalYear":"1960","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000179644","NDDF":"001868","UNII":"XA501VL3VR","VUID":"4019065","CHEBI":"CHEBI:8068","VANDF":"4019065","INN_ID":"553","RXNORM":"203198","UMLSCUI":"C0031411","chemblId":"CHEMBL1201208","ChEMBL_ID":"CHEMBL1201208","KEGG_DRUG":"D05454","DRUGBANK_ID":"DB00830","PUBCHEM_CID":"4762","SNOMEDCT_US":"23532003","SECONDARY_CAS_RN":"13931-75-4","MESH_DESCRIPTOR_UI":"D010633"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Boehringer Ingelheim","relationship":"Original Developer"}],"publicationCount":294,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"originalDeveloper":"Boehringer Ingelheim","recentPublications":[{"date":"2025 Apr","pmid":"39903277","title":"Toxicokinetics and analytical toxicology of the phenmetrazine-derived new psychoactive substance 3,4-methylenedioxyphenmetrazine studied by means of in vitro systems.","journal":"Archives of toxicology"},{"date":"2024 Mar 18","pmid":"38499566","title":"Co-targeting the kappa opioid receptor and dopamine transporter reduces motivation to self-administer cocaine and partially reverses dopamine system dysregulation.","journal":"Scientific reports"},{"date":"2023 Jul-Dec","pmid":"37968919","title":"Stimulant and hallucinogenic novel psychoactive substances; an update.","journal":"Expert review of clinical pharmacology"},{"date":"2023 Jun 1","pmid":"36871726","title":"Target and suspect screening of (new) psychoactive substances in South Korean wastewater by LC-HRMS.","journal":"The Science of the total environment"},{"date":"2022 Nov","pmid":"36028947","title":"Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis.","journal":"Basic & clinical pharmacology & toxicology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Boehringer Ingelheim","companyId":"boehringer-ingelheim","modality":"Small molecule","firstApprovalDate":"1982","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"BOEHRINGER INGELHEIM","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:05:47.374370+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}